Abstract
Antiepileptic drugs (AEDs) are among the best studied medications for the prevention of migraine and other headache disorders. The efficacy profiles of topiramate and valproate in headache prophylaxis are well established relative to those of other AEDs. Clinical data for other AEDs are generally limited, conflicting and/or show a lack of efficacy. Several factors, including the patient’s headache frequency and severity, tolerance of adverse events and the potential for pregnancy, should be considered when selecting an AED for headache prevention.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marmura MJ, Kumpinsky AS. Refining the benefit/risk profile of anti-epileptic drugs in headache disorders. CNS Drugs. 2018;32(8):735–46.
Costa C, Tozzi A, Rainero I, et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain. 2013;14:62.
Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–45.
Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652–61.
Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. Jama. 2004;291(8):965–73.
Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490–5.
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80.
Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153–62.
Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007;47(10):1398–408.
Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251(8):943–50.
Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006;46(4):642–8.
Krymchantowski AV, Jevoux Cda C. Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy. Headache. 2012;52(1):129–32.
Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110(10):979–84.
Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78(13):976–84.
Li Y, Zhang Q, Qi D, et al. Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-small ka, CyrillicB. J Headache Pain. 2016;17:49.
Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–9.
Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17(2):103–8.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
Bou Ghannam A, Pelak VS. Visual snow: a potential cortical hyperexcitability syndrome. Curr Treat Options Neurol. 2017;19(3):9.
Silberstein S, Goode-Sellers S, Twomey C, et al. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013;33(2):101–11.
Silberstein S, Saper J, Berenson F, et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology. 2008;70(7):548–55.
Pascual J, Caminero AB, Mateos V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache. 2004;44(10):1024–8.
Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17(2):109–12.
Author information
Authors and Affiliations
Consortia
Ethics declarations
Conflict of interest
The article was adapted from CNS Drugs 2018;32(8):735–46 [1] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.
Funding
The preparation of this review was not supported by any external funding.
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Consider using selected antiepileptics to reduce the frequency of various types of headaches. Drugs Ther Perspect 35, 176–179 (2019). https://doi.org/10.1007/s40267-019-00602-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-019-00602-2